GlassScriptPhysician profile
Amanda Lockhart
NPI 1891431714
$1,818.12
in general payments reported to CMS, 2019-2025
23 companies · $1,805 in 2025
The $1,805 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $13.29 · 2025: $1,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,818.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $301.39 | 2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $234.35 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $175.36 | 2025 | |
| Abbvie INC. | $175.09 | 2024-2025 | |
| Abbott Laboratories | $144.37 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $143.52 | 2025 | Airsupra, Breztri, Farxiga |
| Axsome Therapeutics, INC. | $87.28 | 2025 | Auvelity, Symbravo |
| Lilly USA, LLC | $80.11 | 2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $62.69 | 2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $58.55 | 2025 | Nexletol |
| Glaxosmithkline, LLC. | $38.80 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $37.75 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $37.55 | 2025 | |
| Cequr Corporation | $35.48 | 2025 | Cequr Simplicity |
| Astellas Pharma US INC | $35.36 | 2025 | Veozah |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $32.27 | 2025 | Gemtesa |
| Inspire Medical Systems, INC. | $27.57 | 2025 | Inspire |
| Dexcom, INC. | $22.63 | 2025 | Dexcom G6 Transmitter |
| Viatris Specialty LLC | $20.20 | 2025 | Yupelri |
| Lundbeck LLC | $19.07 | 2025 | Vyepti |
| Azurity Pharmaceuticals, INC. | $17.43 | 2025 | Alvesco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.16 | 2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $14.14 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Lockhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.